Drugs / PSMA-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not stated1 trial | ||||||
| — | NCT04825652 | — | castration-resistant prostate carcinoma | Advanced Accelerator Applications | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03181867 Background | Aug 2017 → Feb 2031 expected | prostate cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSMA-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03181867 ↗ |
| Modality | Diagnostic / imaging agent | “PSMA-11 is used to confirm the presence of PSMA positive lesions in patients, which then makes them eligible for treatment with 177Lu-PSMA-617.” NCT04825652 ↗ |
| Route | Other | “a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.” NCT03181867 ↗ |